While radiotherapy remains a key therapy for many cancers, in recent years, DNA repair inhibitors, particularly PARP inhibitors, and immunotherapy, specifically immune-checkpoint inhibitors, have progressively shown great therapeutic potential in several experimental and clinical settings. Here, PARP1 is linked to cancer.